Targeting melanoma with 211At/131I-methylene blue: Preclinical and clinical experience

Hybridoma

Volumn 18, Issue 1, 1999, Pages 77-82

  Link, E M ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; INTERMEDIN; IODINE 131; MELANIN; METHYLENE BLUE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RADIOISOTOPE; ASTATINE; DIAGNOSTIC AGENT; DRUG CARRIER; RADIOACTIVE IODINE;

ALPHA RADIATION; ANIMAL MODEL; ANIMAL TISSUE; BINDING AFFINITY; CHEMICAL STRUCTURE; CHRONOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; EARLY DIAGNOSIS; ELECTRON; HAMSTER; IODINE 131 UPTAKE TEST; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DECAY; SCINTILLATION CAMERA; ANIMAL; HUMAN; REVIEW;

ANIMALIA; CRICETINAE;

ANIMALS; ASTATINE; DRUG CARRIERS; HUMANS; IODINE RADIOISOTOPES; MELANOMA; METHYLENE BLUE; MICE;

EID: 0032588689     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.77     Document Type: Conference Paper

References (34)

1. Delaunay MM: Prognostic factors in melanoma. In: Diagnosis and Management of Melanoma in Clinical Practice. Kirham N, Cotton DWK, Lallemand RC, White J, and Rosin RD (Eds.). Springer-Verlag, London, 1992, pp. 97-112.
2. Conforti AM, Ollila DW, Kelly MC, Gammon G, and Morton DL: Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 1997;66:55-64.
3. Bonnekoh B, Bickenbach JR, and Roop DR: Immunological gene therapy approaches for malignant melanoma. 1. Tumour-immunological background. Skin Pharmacol 1997;10:49-62.
4. Bonnekoh B, Bickenbach JR, and Roop DR: Immunological gene therapy approaches for malignant melanoma. 2. Pre-clinical studies and clinical strategies. Skin Pharmacol 1997;10:105-125.
5. Willis RA: The melanoma. In: Pathology of Tumors. Butterworths, London, 1967, pp. 915-936.
6. Mishima Y: Molecular and biological control of melanogenesis through tyrosinase genes and intrinsic and extrinsic regulatory factors. Pigment Cell Res 1994;7:376-387.
7. Liewendahl K, and Pyrhönen S: Radioimmunodetection and radioimmunotherapy of malignant melanoma. Acta Oncol 1993;32: 717-721.
8. Wraight EP, Bard DR, Maughan TS, et al.: The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992;65:112-118.
9. Olander K, Larsson B, Olander K, et al.: False precursors of melanin as selective melanoma seekers. Br J Cancer 1979;39: 449-452.
10. Ings RMJ: The melanin binding of drugs and its implications. Drug Metabolism Rev 1984;15:1183-1212.
11. Potts AM: The reaction of uveal pigment in vitro with polycyclic compounds. Invest Ophthalmol Vis Sci 1964;3:405-416.
12. Foster R, and Hanson P: Electron-donor-acceptor complex formation by compounds of biological interest. I. Optical absorption spectra of mixtures of phenothiazines and related compounds with electron acceptors. Biochim Biophys Acta 1966;112:482-489.
13. Foster R, and Fyfe CA: Electron-donor-acceptor complex formation by compounds of biological interest. II. The association-constant of various 1,4-dinitrobenzene-phenothiazine drug complexes. Biochim Biophys Acta 1966;112:490-495.
14. Larsson B, and Tjälve H: Studies on the mechanism of drug binding to melanin. Biochem Pharmacol 1979;28:1181-1187.
15. Ehrlich P, and Leppmann A: Uiber schmerzstillende Wirkung des Methylenblau. Deutsche Med Wchnschr 1890;16:493-497.
16. DeEds F, Stockton AB, and Thomas JO: Studies on phenothiazine. VIII. Antiseptic value of phenothiazine in urinary tract infections. J Pharm Exp Ther 1939;65:353-371.
17. Brooks MM. Methylene blue as antidote for cyanide and carbon monoxide poisoning. J Am Med Assoc 1933;100:59.
18. Ellenhorn MJ, and Barceloux DG: In: Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Elsevier, Amsterdam, 1987, pp. 844-852.
19. Martindale, The Extra Pharmacopoeia, 28th ed. Reynolds JEF (Ed.). The Pharmaceutical Press. London, 1982, pp. 384-385.
20. Humm J: A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1987;13:1767-1773.
21. Link EM, and Lukiewicz S: A new radioactive drug selectively accumulating in melanoma cells. Eur J Nucl Med 1982;7:469-473.
22. 211At-methylene blue for pigmented melanoma in animal model system. Cancer Res 1989;49:4332-4337.
23. 131I. Radiother Oncol 1988;11:133-142.
24. Link EM, and Rydzy M: Endoirradiation of neoplastic tissues by administered radioisotopes. In: Proceedings of the Third Meeting of the Polish Biophysics Society, Warsaw, Poland, 1978, p. 62.
25. Link EM, Costa DC, Lui D, Ell PJ, Blower PJ, and Spittle MF: Targeting disseminated melanoma with radiolabelled methylene blue: Comparative bio-distribution studies in man and animals. Acta Oncologica 1996;35:331-341.
26. Fatt I, and Weissman BA: Physiology of the Eye: An Introduction to the Vegetative Functions, 2nd ed. Butterworth-Heinemann, Boston, 1992.
27. Dubois D, Ledermann JA, Link EM, Stauss H, and Collins M: Malignant melanoma. Lancet 1992;340:948-951.
28. Link EM, Blower PJ, Costa DC, Lane D, Lui D, Brown RSD, Ell PJ, and Spittle MF: Early detection of melanoma metastases with radioiodinated methylene blue. Eur J Nucl Med 1998;25:1322-1329.
29. Link EM, Costa DC, Lane D, Blower PJ, and Spittle MF: Radioiodinated methylene blue for diagnosing early melanoma metastases. Lancet 1996;348:753.
30. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Treatment of micrometastases. Cancer Res 1990;50:2963-2967.
31. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Treatment of cutaneous tumors and lymph node metastases. Cancer Res 1992;52: 4385-4390.
32. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Dose fractionation in the treatment of cutaneous tumours. Eur J Cancer 1996;32A:1240-1247.
33. 211At-methylene blue in targeted radiotherapy of disseminated melanoma. Pigment Cell Res 1994;7:358-362.
34. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Microscopic analysis of tumour vs. normal tissue damage. Eur J Cancer 1996;32A:1986-1994.